Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma
Troy Puar1, Anouk van Berkel1, Martin Gotthardt1
1Department of Internal Medicine (T.P., A.v.B., A.R.M.M.H., H.J.L.M.T.), Division of Endocrinology, Department of Radiology and Nuclear Medicine (M.G.), and Department of Internal Medicine (J.W.M.L.), Division of Vascular Medicine, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands; Department of Endocrinology (T.P.), Changi General Hospital, Singapore 529889, Singapore; Department of Internal Medicine (B.H.), Division of Endocrinology, and Department of Human Biology (W.D.v.M.L.), NUTRIM School for Nutrition, Toxicology, and Metabolism, and Department of Medical Imaging (B.B.), Division of Nuclear Medicine, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands; Department of Medicine and Institute of Clinical Chemistry and Laboratory Medicine (J.W.M.L.), University Hospital Carl Gustav Carus, 01307 Dresden, Germany; and Centre for Quantitative Medicine (Y.X.), Duke-National University Singapore Graduate Medical School, Singapore 169856, Singapore.
Context:
Patients with pheochromocytomas and paragangliomas (PGLs) may have brown adipose tissue (BAT) activation induced by catecholamine excess. (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) can be used for the localization of both PGLs and BAT. It is unknown whether BAT is specifically affected by altered cellular energy metabolism in patients with SDHx- and VHL-related PGLs.
Objective:
The objective of the study was to determine endocrine and paracrine effects of catecholamine excess on BAT activation in patients with PGLs as detected by (18)F-FDG PET/CT, taking into account genetic variation.
Design:
Patients with PGLs who were fully genetically characterized underwent presurgical (18)F-FDG PET/CT imaging for tumor localization and to quantify BAT activation.
Setting:
The study was conducted at a single Dutch tertiary referral center.
Patients And Intervention:
Seventy-three patients, aged 52.4 ± 15.4 years, with a body mass index of 25.2 ± 4.1 kg/m(2), mean ± SD, were grouped into sporadic, cluster 1 (SDHx, VHL) and cluster 2 (RET, NF1, MAX) mutations.
Main Outcome Measures:
(18)F-FDG mean standard uptake values were assessed in predefined BAT locations, including perirenal fat.
Results:
Twenty-one of 73 patients (28.8%) exhibited BAT activation. BAT activation was absent in all six patients with nonsecreting PGLs. No difference in (18)F-FDG uptake by perirenal fat on the side of the pheochromocytoma and the contralateral side was observed (mean standard uptake value of 0.80 vs 0.78, respectively, P = .42). The prevalence of BAT activation did not differ between sporadic (28.9%), cluster 1 (40.0%), and cluster 2 patients (15.4%, P= .36).
Conclusion:
Patients with PGLs exhibit a high prevalence of BAT activation on (18)F-FDG PET/CT. This is likely due to systemic catecholamine excess. BAT activation is not associated with specific germline mutations.
![Visualization and Quantification of Brown and Beige Adipose Tissues in Mice using [18F]FDG Micro-PET/MR Imaging](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62460.jpg&w=3840&q=50)
Related Concept Videos
01:31Sympathetic Signaling
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
01:16Sympathetic Activation
01:27Sympathetic Pathways: Collateral Ganglia and Adrenal Medulla
Collateral Ganglia
Sympathetic preganglionic axons reach the collateral ganglia along the route of splanchnic nerves. These nerves bypass the sympathetic trunk and communicate with sympathetic postganglionic neurons housed in the prevertebral ganglia. These ganglia supply the organs of the abdominopelvic cavity.
The greater splanchnic nerve, formed by the...
01:09GPCRs Regulate Adenylyl Cylase Activity
01:25cAMP-dependent Protein Kinase Pathways
02:23Abnormal Proliferation